Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523572 · ClinicalTrials.gov registry record · Phase 1
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT03523572 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 86 participants.
The verdict
NCT03523572, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is a study of trastuzumab deruxtecan for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens. Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab. The study will be done in two parts: * Part 1 is to identify the recommended dose to use for treatment. * Part 2 is to find out how well the combination works, and how safe and tolerable it is.
Interventions
- DRUG Nivolumab
- DRUG Trastuzumab deruxtecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523572
The ClinicalTrials.gov registry entry for NCT03523572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03523572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523572 about?
NCT03523572 is a clinical study titled "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer". This is a study of trastuzumab deruxtecan for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens. Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab....
What is the current status of trial NCT03523572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2018-08-02. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT03523572?
The interventions under investigation include: Nivolumab (DRUG), Trastuzumab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT03523572?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.